bioMerieux S.A.

Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
  • TickerBIM
  • ISINFR0013280286
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/19/2019

...

Christophe-Raphaël Ganet

bioMerieux : Agreement with Baxter in identifying acute kidney injury

>R&D collaboration - R&D collaborationBaxter and bioMérieux announce their collaboration to improve the identification and treatment of acute kidney injury (AKI). The agreement, the details of which are not disclosed (bioMérieux should receive fees in the agreement and partnership line of its revenues, followed by sales or royalty revenues), provides for the development of future biomarkers to quickly identify AKI and provide information for treatment. AKI i...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 19/03/2019

...

Christophe-Raphaël Ganet

bioMérieux : Accord avec Baxter dans l’identification de l’insuffisance rénale aiguë (IRA)

>Collaboration R&D - Baxter et bioMérieux annoncent leur collaboration pour améliorer l'identification et le traitement de l’insuffisance rénale aiguë. L’accord, dont les détails ne sont pas communiqués (bioMérieux devrait percevoir des fees dans la ligne accord et partenariat de ses revenus, puis des revenus de ventes ou royalties), prévoit le développement de futurs biomarqueurs permettant d’identifier rapidement l’insuffisance rénale aiguë (IRA) et de donner des in...

Christophe-Raphaël Ganet

bioMerieux : Agreement with Baxter in identifying acute kidney injury

>R&D collaboration - R&D collaborationBaxter and bioMérieux announce their collaboration to improve the identification and treatment of acute kidney injury (AKI). The agreement, the details of which are not disclosed (bioMérieux should receive fees in the agreement and partnership line of its revenues, followed by sales or royalty revenues), provides for the development of future biomarkers to quickly identify AKI and provide information for treatment. AKI i...

Christophe-Raphaël Ganet

bioMérieux : Accord avec Baxter dans l’identification de l’insuffisance rénale aiguë (IRA)

>Collaboration R&D - Baxter et bioMérieux annoncent leur collaboration pour améliorer l'identification et le traitement de l’insuffisance rénale aiguë. L’accord, dont les détails ne sont pas communiqués (bioMérieux devrait percevoir des fees dans la ligne accord et partenariat de ses revenus, puis des revenus de ventes ou royalties), prévoit le développement de futurs biomarqueurs permettant d’identifier rapidement l’insuffisance rénale aiguë (IRA) et de donner des in...

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - BIOMERIEUX : Résultats solides, valorisation excessive - VENTE, OC 57€ (vs 51€)

Michael Waterhouse

Morningstar | BioMerieux Posts Solid 4Q and 2019 Outlook; Slightly Raising Our FVE

We’re raising our fair value estimate for BioMerieux as the company’s 10% organic revenue growth during the fourth quarter combined with an outlook of between 7% and 8.5% growth for 2019 both surpass our expectations. An increase in marketing costs offsets a portion of the top-line performance leaving us within management’s adjusted operating income of EUR 385 to EUR 400 million of the year. Regardless, the slight increase in our revenue outlook while keeping most of our long-term margin assumptions in place puts our new fair value estimate at EUR 50 per share. While we still have some concern...

Michael Waterhouse

Morningstar | BioMerieux Posts Solid 4Q and 2019 Outlook; Slightly Raising Our FVE. See Updated Analyst Note from 06 Mar 2019

We’re raising our fair value estimate for BioMerieux as the company’s 10% organic revenue growth during the fourth quarter combined with an outlook of between 7% and 8.5% growth for 2019 both surpass our expectations. An increase in marketing costs offsets a portion of the top-line performance leaving us within management’s adjusted operating income of EUR 385 to EUR 400 million of the year. Regardless, the slight increase in our revenue outlook while keeping most of our long-term margin assumptions in place puts our new fair value estimate at EUR 50 per share. While we still have some concern...

1 director sold

A director at Biomerieux sold 10,000 shares at 75.584EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/19/2019

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 19/03/2019

...

Alain William ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Louis Boujard
  • Philippe Ourpatian
  • Pierre Tegner
  • Rémi Adam
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/27/2019

This is the thirteenth update of our report on Corporate Governance large caps Europe. We have analysed 125 of the European companies covered by ODDO BHF analysts. In the Strong opportunities (1), we favour five stocks: Unibail Rodamco (Buy, target price € 190.0), AXA (Buy, target price € 28.0), Veolia (Buy, target price € 30.0), Danone (Buy, target price € 81.0) and Michelin (Buy, target price € 130.0). - Cf. report published today. - ...

Alain William ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Louis Boujard
  • Philippe Ourpatian
  • Pierre Tegner
  • Rémi Adam
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 27/02/2019

13ème mise à jour de notre étude Corporate Governance Large caps Europe. Nous avons étudié 125 valeurs, toutes suivies par les analystes d’Oddo BHF. Nous privilégions 5 valeurs dans les opportunités fortes : Unibail Rodamco (Achat, OC 190.0 €), AXA (Achat, OC 28.0 €), Veolia (Achat, 30.0 €), Danone (Achat, 81.0 €) et Michelin (Achat, 130.0 €). Cf. étude publiée ce matin. - ...

Ahmed Ben Salem ...
  • Alain William
  • Alfred Glaser
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jean Sassus
  • Jerôme Bodin
  • Johanna Jourdain
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Corby
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Sylvain Goyon
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/07/2019

The stabilisation of eurozone PMI indices in January contributes, albeit still modestly, to the abating of the excessive risk aversion end-2018. This is in addition to the welcome change in the Fed’s tone with the announced pause in monetary normalisation, pushing back the spectre of recession. Against this backdrop, the decent nature of results publications is contributing to the improvement in sentiment. However, questions about growth, or rather its rate of deceleration, persist. I...

BIOMERIEUX SA sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to BIOMERIEUX SA (FR), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date January 15, 2019, the closing price was EUR 58.50 and its target price was estimated at EUR 51.22.

MarketLine Department

Bio-Rad Laboratories, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Bio-Rad Laboratories, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bio-Rad Laboratories, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

MarketLine Department

Great Basin Scientific Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Great Basin Scientific Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Great Basin Scientific Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

Biomérieux - Assemblée générale des actionnaires du 23 mai 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Proxy Report - 17/05/2018

La fin de l'exercice 2017 fût marquée par la nomination d'Alexandre Mérieux, ancien Directeur Général Délégué de la société, en qualité de Président-Directeur Général pour succéder à Jean-Luc Bélingard. Il est regrettable que la société n'ait pas profité de ce changement au sein de la direction pour séparer les fonctions de Président et de Directeur Général. Cette année encore, Proxinvest ne soutiendra pas la rémunération attribuée à Jean-Luc Bélingard et Alexandre Mérieux pour des raisons similaires à l'année dernière (Résolution 10 et 11) : une rémunération différée revue à la hausse sur la...

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 70,40 € prochainement. Le prochain objectif est à 63,02 €, puis 58,70 €. Le franchissement de 74,56 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BIOMERIEUX : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €70.40. The next target is at €63.02, then €58.70. Passing €74.56 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 63,02 €. La tendance baissière serait remise en cause au-dessus de 74,56 €.

Jérôme VINERIER

Short term view - BIOMERIEUX : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €63.02. The bearish trend would be challenged above €74.56.

Jérôme VINERIER

Analyse moyen terme - BIOMERIEUX : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch